How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak Kanishka Das Jul 27, 2026 Kimmtrak anchors IMCR today, but its broader T-cell receptor platform is targeting larger cancer, infectious disease and autoimmune markets.
